Therapeutic Advances for Metastatic NSCLC With EGFR Exon 20 Insertion Mutations
Zofia Piotrowska, MD, a thoracic medical oncologist, explores the challenges of managing patients with EGFR exon 20 insertion mutations in non-small cell lung cancer.
Archives: ClinicianPOV
Emerging Role of Selective RET Inhibitors in RET-Dependent Cancers
Clinical trialist and physician investigator Vivek Subbiah, MD, discusses advances in targeting RET-dependent cancers.
Targeting MET Exon 14 Skipping Mutations in Non-Small Cell Lung Cancer
Paul K. Paik, MD, a medical oncologist specializing in the care of patients with lung cancer at Memorial Sloan Kettering Cancer Center, in New York, discusses targeted therapies to treat patients with NSCLC harboring MET exon 14 skipping mutations.
Decision-Making for Patients With IDH1-Mutated Relapsed or Refractory Acute Myeloid Leukemia
Hematologic oncologist and clinical researcher Eytan M. Stein, MD, discusses treatment options for patients with IDH1-mutated relapsed or refractory acute myeloid leukemia.
Addressing Steroid-Refractory Acute Graft-vs-Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation
Hematologic oncologist and clinical researcher Doris M. Ponce, MD, discusses strategies to prevent and treat graft-vs-host disease after allogeneic hematopoietic stem cell transplantation.
Achieving Testosterone Suppression in Advanced Prostate Cancer
Advanced prostate cancer is a spectrum of disease states with varying clinical characteristics. Oncologist and clinical researcher Neal D. Shore, MD, FACS, discusses the latest androgen-deprivation therapies for advanced prostate cancer.
PD-L1 Inhibitors for the Treatment of Extensive-Stage Small Cell Lung Cancer
Most patients with extensive-stage small cell lung cancer (SCLC) have a poor prognosis. In this interview with oncologist and clinical researcher Millie Das, MD, several specific immunotherapies are discussed as potential first-line standard of care for patients with extensive-stage SCLC.
PD-L1–Positive Recurrent or Metastatic Triple-Negative Breast Cancer
Enthusiasm for immunotherapy combinations in TNBC remains high, based on signals of efficacy observed in large phase 3 studies.
Selecting Therapy for Patients With Metastatic Pancreatic Cancer After Disease Progression
Igor Astsaturov, MD, PhD, of the Fox Chase Cancer Center in Philadelphia, Pennsylvania, reviewed therapeutic strategies for patients with pancreatic cancer.
Real Progress Made in Relapsed/Refractory Multiple Myeloma, But Questions Remain
Cancer Therapy Advisor discussed progress in the management of relapsed/refractory multiple myeloma with Paul G. Richardson, MD, of the Dana-Farber Cancer Center.
- Loading...
Loading...
Loading... 
Loading...